12:00 AM
 | 
Mar 06, 2000
 |  BC Week In Review  |  Company News  |  Deals

Abgenix, Pfizer deal

Under a two-year extension to a 1997 collaboration, ABGX will use its XenoMouse technology to develop antibodies to two...

Read the full 75 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >